Restless Legs Syndrome: Is Treatable But Under-Recognised
BMJ 333:457-458, Medcalf,P. &Bhatia,K.P., 2006
Glycogen-Storage Disease Type II
eMedicine, May 2, Ibrahim,J. &McGovern,M., 2006
Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Neurorehabil Neural Repair 19:259-263, Dobkin,B.H., 2005
Treatment of Early Onset Multiple Sclerosis With Subcutaneous Interferon Beta-1a
Neurol 64:888-890, 778, Pohl,D., et al, 2005
Two Patients With COMT Inhibitor-Induced Hepatic Dysfunction and UGT1A9 Genetic Polymorphism
Neurol 65:1820-1822, Martignoni,E.,et al, 2005
Clinicopath Conf, Human Granulocytic Ehrlichiosis
NEJM 352:1358-1364, Case 10-2005, 2005
Ximelagatran vs Warfarin for Stroke Prevention in Patients with Nonvalvular Atrial Fibrillation
JAMA 293:690-698,736, SPORTIF Executive Steering Committee for the SPORTIF V Investigators, 2005
Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004
The Metabolic Syndrome, Inflammation, and Risk of Cognitive Decline
JAMA 292:2237-2242, Yaffe,K.,et al, 2004
Liver Injury Associated with the B-Interferons for MS
Neurol 62:628-631, Tremlett,H.L.,et al, 2004
The New Antiepileptic Drugs, Scientific Review
JAMA 291:605-614, LaRoche,S.M.&Helmers,S.L., 2004
Amyloid Myopathy Presenting with Distal Atrophic Weakness
Muscle Nerve 29:605-609, Smestad, C.,et al, 2004
Polymyositis and Dermatomyositis
Lancet 362:971-982, Dalakas,M.C.&Hohlfeld,R., 2003
Treatment of Wilson Disease With Ammonium Tetrathiomolybdate, III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Arch Neurol 60:379-385, Brewer,G.J.,et al, 2003
Stroke Prevention with the Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin in Patients with Non-Valvular Atrial Fibrillation (SPORTIF III): Randomised Controlled Trial
Lancet 362:1691-1698,1686, Executive Steering Committee on Behalf of the SPOR, 2003
Acute Mycoplasma Pneumoniae Infection Presenting as Cholestatic Hepatitis
J Clin Microbiol 41:514-515, Grullich, C.,et al, 2003
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Clinicopath Conf, Hyperviscosity Syndrome Due to IgG Multiple Myeloma
NEJM 346:603-610, Case 6-2002, 2002
Urinary Tract Infection and Coma
Lancet 360:996, De Jonghe,B.,et al, 2002
Neurological Presentation of Fabry's Disease in a 52 Year Old Man
JNNP 73:340-342, Mohanraj,R.,et al, 2002
Giant-cell Arteritis
NEJM 347:272-278, Case 23-2002, 2002
Long-term Treatment of Acromegaly With Pegvisomant, a Growth Hormone Receptor Antagonist
Lancet 358:1754-1759,1743, van der Lely,A.J.,et al, 2001
Clinicopath Conf,Systemic Sclerosis with Scleroderma Renal Crisis
NEJM 345:596-605, Case 26-2001, 2001
Postpartum Blindness
Lancet 358:1338, Jurgensen,J.S.,et al, 2001
Fulminant Liver Failure During Interferon Beta Treatment of Multiple Sclerosis
Neurol 56:1416, Yoshida,E.M.,et al, 2001
Acute Hepatic Encephalopathy with Diffuse Cortical Lesions
Neuroradiology 43:551-554, Arnold, S.M.,et al, 2001
Cerebral Venous Thrombosis Associated with Epoetin Alfa Therapy
Arch Neurol 57:260-262, Finelli,P.F.&Carley,M.D., 2000
Valproate, Hyperandrogenism, and Polycystic Ovaries
Arch Neurol 57:1064-1068, Isojarvi,J.I.T. & Tapanainen,J.S., 2000
Tolcapone and Hepatotoxic Effects
Arch Neurol 57:263-267, Olanow,C.W.&Tasmar Advisory Panel, 2000
Multiple Sclerosis, Side Effects of Interferon Beta Therapy and Their Management
Neurol 53:1622-1627, Walther,E.U.&Hohlfeld,R., 1999
Muscle Pain after Exercise
Lancet 353:1062, Nielen,C.&Mazzone,P., 1999
Disorientation and Vertebral Fractures
Lancet 353:1848, McConnaughey,D.,et al, 1999
Amyloid Myopathy:An Underdiagnosed Entity
Ann Neurol 43:719-728, Spuler,S.,et al, 1999
Medical Complications in Long-Term Survivors with X-Linked Myotubular Myopathy
J Pediatr 134:206-214, Herman,G.E.,et al,, 1999
Riluzole-Induced Pancreatitis
Neurol 52:892-893, Drory,V.E.,et al, 1999
Agranulocytosis Associated with Lamotrigine
BMJ 318:1179, DeCamargo,O.A.K., 1999
Tasmar (tolcapone) Labeling Revisions of Package Insert
Roche Laboratories, , 1998
Postpartum Coma
Lancet 351:1700, McCormack,G.,et al, 1998
The Importance of Formal Serum Iron Studies in the Assessment of Restless Legs Syndrome
Neurol 51:912, Aul,E.A.,et al, 1998
Lamotrigine-Associated Anticonvulsant Hypersentivitiy Syndrome
Neurol 51:1171-1175, Schlienger,R.G.,et al, 1998
Wobbly Handwriting
Lancet 351:336, Rosario,M.A.F.,et al, 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
Tolcapone for Parkinson's Disease
The Medical Letter 40:60-61, , 1998
Interferon Treatment for Multiple Sclerosis:Autoimmune Complications May be Lethal
Neurol 50:570-571, Durelli,L.,et al, 1998
Permanent Visual Loss and Cerebrovascular Accidents in Giant Cell Arteritis: Predictors and Response to Treatment
Arthritis Rheum 41:1497-1504, Gonzalez-Gay,M.,et al, 1998
A Case of Acute Monocytic Ehrlichiosis with Prominent Neurologic Signs
Neurol 48:1619-1623, Grant,A.C.,et al, 1997
Neurological Disturbances Due to Filgrastim
Lancet 349:402-403, Schrijvers,D.,et al, 1997
Serum Creatinine Concentration and Risk of Cardiovascular Disease
Stroke 28:557-563, Wannamethee,S.G.,et al, 1997
Antibiotic Treatment for Giant-Cell Arteritis
Lancet 348:1630, Fontana,P.E.,et al, 1996
Nonsystemic Vasculitic Mononeuropathy Multiplex, Cryoglobulinemia, and Hepatitis C
Muscle & Nerve 19:1596-1602996., David,W.S.,et al, 1996